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Abstract 
In this review we identify potential targets for the therapeutic effects of heparin in asthma 
and chronic obstructive pulmonary disease (COPD), consider the safety and delivery 
modalities of this therapeutic approach. Specifically, we point to the anti-inflammatory, 
antioxidant and mucolytic effects of unfractionated heparin with potential to modify disease 
progression in COPD and asthma when administered via the inhaled route. Inhaled heparin 
may represent an effective add-on therapy in COPD and asthma patient groups, especially 
when taking into consideration the relative deficiency in endogenous heparin reported in 
asthma patients  
 
 
Page 2 of 15
Ac
ce
pte
d M
an
us
cri
pt
 
 
Highlights
  
• Heparin is a unique molecule in biology with multiple pharmacological properties 
• Heparin therapy has benefits in patients with COPD and asthma 
• Inhaled heparin is safe and without adverse events associated with anti-coagulation 
 
 
 
Introduction 
The pathogenesis of asthma and COPD  
Asthma and chronic obstructive pulmonary disease (COPD) are clinical conditions affecting 
millions of people world-wide [1]. The prevalence of COPD is increasing globally and it is 
predicted to be the third major cause of death world-wide by 2020, with over 3 million 
deaths due to COPD in 2012 [1].  Asthma and COPD are characterised by chronic bronchial 
airway inflammation and mucus hypersecretion which are associated with airflow limitation.  
In asthma, airflow is acutely limited, reversibly, by mast cell activation and release of 
mediators of bronchoconstriction, while there is limited evidence for mast cell activation 
contributing to the irreversible airflow limitation in COPD [2]. In COPD, airflow is further 
limited by small airway inflammation and fibrosis, as well as emphysema and gas trapping in 
the lung.  The aetiology of these diseases is associated with environmental risk factors such 
as allergens and pollutants in asthma, and cigarette smoking, indoor smoke particles and 
outdoor pollution in COPD, interacting with susceptibility genes [3, 4].  Acute exacerbation 
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of symptoms requiring hospitalisation are predominantly induced by rhinovirus (RV) 
infection of the respiratory tract as well as allergen exposure in asthma, while in COPD 
exacerbations are predominantly caused by viral (RV, respiratory syncytial virus  and 
influenza virus) or bacterial infections or both [5]. 
The inflammatory cell profile in asthma is typically eosinophilic and driven by a Th2 (IL-4, IL-
13, IL-5) cytokine profile that is responsive to corticosteroid therapy. However, neutrophilic 
inflammation in the airway is also present during exacerbation and is associated with 
asthma severity and resistance to corticosteroid therapy.  Neutrophilic inflammation in 
asthma has been associated with TH1 (IFNγ), Th17 (IL-17) and IL-8 expression and combined 
eosinophilic/neutrophilic inflammation may be a biomarker of the most severe form of 
asthma [6]. 
Airway inflammation in stable COPD is characterised by increased numbers of macrophages, 
neutrophils, dendritic cells, T-cells and B-cells, and increased numbers of airway neutrophils 
correlate with disease severity.  COPD exacerbations induced by bacteria or viruses are 
accompanied by increased numbers of neutrophils in the airway driven by an increase in IL-8 
concentrations in the airway, while the additional presence of airway eosinophils is 
associated with viral infections and increased Th2 cytokine production [7].  
Oxidative stress is a feature of bronchial asthma [8] and COPD, with wide-ranging effects in 
the airways and lung parenchyma in COPD [9]. Reactive oxygen species (ROS) may be from 
exogenous sources such as pollution and cigarette smoke, as well as endogenous sources 
including activated neutrophils and eosinophils, and ROS drive further inflammation. 
Multiple biological effects of ROS include activation of the pro-inflammatory transcription 
factor NF-kB, activation of histone acetyl transferase and inhibition of histone deacetylase2 
(HDAC2) which together enhance inflammatory gene transcription and corticosteroid 
resistance. Further effects of ROS include oxidative damage to proteolytic defences such as 
the elastase inhibitors alpha1-antitrypsin and secretory leukocyte protease inhibitor (SLPI), 
pathological changes in respiratory epithelial cells and mucus hypersecretion [8, 9].  
Genetic and acquired defects in airway epithelial cell function have been described in 
asthma [10] and COPD [11], respectively.  Defective epithelial barrier function in asthma is 
the result of the epithelium being both inherently fragile and susceptible to damage by 
exogenous pathogens, ROS, allergens and particulate matter, as well as endogenous 
eosinophil-derived cationic proteins [12], while having an impaired repair response [10]. 
Oxidative and nitrosative stress may play a role in elastase-induced lung tissue damage and 
emphysema [13] with genetic and acquired defects in antioxidant function contributing to 
the role of oxidative stress in COPD [14]. 
Mucus hypersecretion is a feature of many patients with asthma [10] and many, if not all, 
patients with COPD, in whom mucus hypersecretion increases with airflow limitation but is 
not always associated with chronic cough and sputum production [15]. EGFR-mediated 
goblet cell hyperplasia is a feature of both asthma and COPD [9, 10], with increased 
secretion of mucus containing the gel-forming mucin MUC5AC in response to EGFR-
mediated activation of goblet cells by endogenous ligands (EGF, TGFα), ROS and IL-13 and 
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MUC5 from mucus glands [16].  Neutrophil elastase is a potent activator of EGFR via 
cleavage of the membrane-anchored pro-TGFα from the epithelial surface and release of 
mature TGFα which binds and activates EGFR and mucin synthesis [9]. Following secretion, 
mucus may be relatively dehydrated, making it difficult to clear, as a consequence of 
acquired defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein 
function in both COPD and, more controversially, in asthma [11]. 
Neutrophil elastase plays a major role in the pathogenesis of COPD and severe asthma not 
only as a mediator of mucus hypersecretion, but in driving the protease/antiprotease 
imbalance through proteolytic inactivation of the tissue inhibitor of metalloproteinases-1 
(TIMP-1) and SLPI, a potent inhibitor of elastase activity [6,9]. Increased elastase activity in 
COPD contributes to tissue damage and emphysema, as well as further cycles of 
neutrophilic inflammation by augmenting epithelial IL-8 expression and generating 
neutrophil chemoattractant matrikines [9]. Neutrophil elastase activity cripples the immune 
response and mucociliary clearance in patients with cystic fibrosis [17], and may similarly be 
responsible for defective mucus clearance in asthma and COPD, mucus obstruction of the 
airways and susceptibility to infection.   
Neutrophil elastase is found in association with neutrophil extracellular traps (NETs). NETs 
are formed from decondensed nuclear DNA, released in response to generation of 
intracellular ROS and elastase-mediated degradation of nuclear histones, which bind 
antimicrobial factors to form a physical and chemical barrier to the spread of pathogens. 
NETs are involved in the elimination of pathogens however, in excess, they also contribute 
to airway obstruction and tissue damage in both asthma and COPD [6, 18]. IL-8 is a potent 
NET inducer and NETs are present in COPD patients with both stable disease and during 
acute exacerbations, and correlate with the severity of airflow limitation [18]. Eosinophil 
extracellular traps (EETs) are also present in both asthmatic and COPD airways, and may be 
composed of nuclear or mitochondrial DNA [18, 19]. Further, it has recently been suggested 
that early formation of EETs triggers disease pathogenesis in COPD [19]. NETs and EETs are 
therefore therapeutic targets in asthma and COPD.  
Heparin 
Heparin is a member of the glycosaminoglycan family of linear, anionic, polysaccharides 
consisting of repeating disaccharide units, with variable degrees of sulphation and therefore 
considerable microheterogeneity in the structure [20]. Its biological synthesis generates 
highly diverse polysaccharide chains, only a third of which contain the pentasaccharide 
sequence responsible for binding and activation anti-thrombin III (ATIII) and the anti-
coagulation properties of heparin.  Medicinal heparin is derived from pig intestinal mucosa 
[21] and has an average molecular weight range of 12-16,000 for the size-unfractionated 
heparin. Low molecular weight heparins are derived from unfractionated heparin by various 
chemical processes generating heparins with average molecular weights from 3,600 to 
6,500 depending on the process [22].  
The multiple pharmacological effects of heparin 
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Heparin has the highest negative charge of any molecule in biology and multiple protein 
binding partners [20]. Many of these interactions are charge-dependent although in some 
cases a specific saccharide protein-binding sequence has been determined (as for AT-III).  As 
a result, heparin has multiple pharmacological properties beyond anti-coagulation that are 
independent of its anti-coagulant activity [20, 23]. These include the anti-inflammatory 
effects of heparin and inhibition of each of the steps involved in inflammatory cell 
recruitment; inhibition of neutrophil activation and degranulation, inhibition of the steps 
leading to transendothelial migration of neutrophils, including rolling and adhesion, 
platelet/leukocyte interactions and inhibition of heparanase activity [20]. The major 
chemokine directing neutrophil recruitment into lung tissue is IL-8 bound to endothelial cell-
surface proteoglycans. Heparin displaces, binds and inhibits the chemotactic activity of IL-8 
by forming a complex with IL-8 that is unable to activate its receptor [24].  
These anti-inflammatory effects are likely to combine to reduce the numbers of activated 
neutrophils in the lung, and consequently the burden of neutrophil elastase activity and 
NETs in the airway.  Additionally, unfractionated heparin and low molecular weight heparin 
(LMWH) are equally able to inhibit elastase release from activated neutrophils, and even  
shorter saccharide chains derived from LMWH, with a minimum chain length of ten 
saccharides, are also effective [25]. However, the short chain saccharides and the LMWH 
from which they are derived were not effective inhibitors of neutrophil adhesion to 
endothelial cells [25]. Further, pre-clinical studies have indicated that unfractionated 
heparin is a considerably more potent local anti-inflammatory agent than low molecular 
weight heparin (dalteparin sodium) or a selectively 2 and 3-O desulphated non-
anticoagulant derivative of heparin [26].   
Further, heparin has direct inhibitory effects on neutrophil elastase and cathepsin G that 
correlate positively with the saccharide chain length and degree of sulphation [27].  In view 
of the fact that elastase is a potent mucus secretagogue and tissue elastolytic enzyme there 
are multiple beneficial effects of reducing the elastase burden in COPD and severe asthma, 
which should overall restore mucociliary clearance and the protease/antiprotease balance, 
while limiting tissue damage.  Delivery of exogenous protease inhibitors for the treatment of 
COPD has been proposed to have many advantages [28], and inhaled unfractionated 
heparin may be a promising candidate. 
The anti-oxidant activity of heparin [29] may further reduce inflammation, protect anti-
proteases from oxidative inactivation and limit ROS-induced mucus hypersecretion. In 
COPD, severe asthma and asthmatics who smoke, HDAC2 is reduced, preventing 
corticosteroids from inactivating activated inflammatory genes. The reduction in HDAC2 
appears to be secondary to increases in oxidative and nitrosative stress in the lungs [30]. 
Antioxidants and inhibitors of nitric oxide synthesis, such as heparin [31], may therefore 
restore corticosteroid sensitivity in COPD. 
The eosinophil cationic proteins major basic protein (MBP) and eosinophil cationic protein 
(ECP) are elevated in airway secretions in asthma, and found in association with EETs [12]. 
Although these basic proteins have roles in host defence against a range of pathogens, they 
are highly cytotoxic, and induce bronchoconstriction and airway hyperresponsiveness. 
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Heparin neutralises the charge on eosinophil basic proteins and inhibits these effects [12, 
32].  Heparin may also inhibit ECP in the inflamed airways and alveoli that is responsible for 
C-fibre stimulation and mucus hypersecretion in asthma and COPD [33, 34].   
Mucus hypersecretion and obstruction of the airways is compounded by the presence and 
NETs and EETs in asthma and COPD sputum.  DNA contributes to sputum elasticity and 
reduced cough clearance, and in cystic fibrosis (CF) sputum we showed that heparin 
disaggregates DNA/actin bundles and activates endogenous DNase to reduce sputum 
elasticity [35]. We see the same effects in sputum from patients with COPD [unpublished, 
but see the graphical abstract], and this is predicted to improve cough clearance in COPD.  
We also showed that when DNase I breaks down DNA, IL-8 encrypted by the DNA is released 
and induces increased neutrophil migration in vitro [36].  Together with release of elastase 
activity [18], this pro-inflammatory effect of DNase alone would potentially be avoided by 
co-administration of DNase I with heparin by inhalation.  
Electrostatic mucin interactions and viscosity are increased by a low pH in airway surface 
liquid, as seen in asthma and COPD, and these effects are reversed by heparin [37]. Further, 
oxidation increases mucin cross-links and the elasticity of sputum [38]. These effects, 
together with the presence of DNA, may contribute to the abnormal viscoelasticity of 
sputum from patients with asthma [39]. Thiol antioxidants such as N-acetyl-L-cysteine 
(NAC), carbocisteine and erdosteine are oral mucolytic drugs that at high doses may 
improve the number of exacerbations in COPD, without impact on airflow obstruction [13, 
40-43].  However, despite the fact that mucus accumulation is a major factor in airway 
obstruction in asthma, no effective mucolytic treatments for asthma exist. We suggest that 
inhaled heparin, through inhibition of mucus hypersecretion and effects on mucus rheology, 
may be an effective mucoregulatory agent and mucolytic drug in asthma and COPD. In 
support of this notion, unfractionated and LMWH inhibited endotoxin and allergen-induced 
nasal mucus secretion and MUC5AC expression by airway epithelial cells directly and 
indirectly, through suppression of neutrophilic and eosinophilic inflammation, in pre-clinical 
models [44, 45]. 
The multiple effects of inhaled unfractionated heparin are illustrated in Figure 1. 
Safety and delivery modalities 
While we and others [46, 47] have reported coagulation and fibrin formation in the 
asthmatic airways, the positive effects of inhaled unfractionated heparin in clinical studies in 
asthma [48, 49] and COPD [50] are unlikely to be associated with the anticoagulant 
properties of heparin as these are neutralised by the plethora of basic proteins present at 
elevated concentrations in inflamed airways in asthma and COPD [50].  Further, 
intrapulmonary heparin does not cross the bronchial mucosa when nebulised at doses up to 
8 mg/kg body weight and no acute or chronic toxicological effects were reported in any 
species, or at any dose, studied [48-51].  The delivered lung dose is determined by the 
nebuliser efficiency and the concentration by the volume of secretions into which heparin is 
delivered.  Bendstrup et al. [52] demonstrated that 8% of the loading dose is delivered to 
the lung from a jet nebuliser and that a lung dose of 32,000 International Units (~160 mg) 
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to the lower respiratory tract can safely be inhaled for clinical or research purposes.  In 
COPD, we have estimated a safe and effective lung dose of 60 mg [50]. 
Since anticoagulation is associated with intravenous and subcutaneous administration of 
heparin, the inhaled route may be safe and effective in asthmatic and COPD patients. 
Further, since systemic delivery and anti-coagulation was achieved by inhalation of dry 
particles of heparin and LMWH [53] or as a liquid instilled via the nasal route [54], then we 
believe that nebulisation and oral inhalation of an aerosol of liquid droplets of 
unfractionated heparin solution is the preferred delivery modality. 
In addition to mucolytic and mucoregulatory effects that are predicted to reduce airway 
obstruction and improve airflow, nebulised unfractionated heparin is proposed to have anti-
inflammatory, anti-oxidant and anti-nitrosative effects that protect the airways and lung 
tissue from damage, as well as reparative effects to restore functional airway epithelium 
[20, 55].  
Clinical trials of heparin in asthma and COPD 
Monagle et al. [48] reviewed 14 studies of inhaled unfractionated and LMWH in adults and 
children with asthma and allergy. These studies reported positive effects of inhaled heparin 
on lung function in allergen and exercise induced asthma, and reduced bronchoconstriction 
following provocation with water, methacholine, adenosine, histamine and hypertonic KCl, 
with no systemic anticoagulation or adverse effects such as pulmonary haemorrhage.  
Table 1 summarises studies investigating the effect of heparin and LMWH in patients with 
COPD.  Positive effects on lung function were seen in all studies, whether heparin was 
administered via the inhaled, subcutaneous or intravenous route. In our RCT of inhaled 
unfractionated heparin in patients with moderate to severe COPD we observed clinically 
significant improvements over a relatively short time in lung function, exercise capacity and 
dyspnea [50]. 
 
Conclusion 
Unfractionated heparin is a drug with a structurally diverse molecular scaffold naturally 
orientated to multiple molecular targets with mucolytic, anti-inflammatory, anti-oxidant and 
wound healing properties. These effects are independent of anti-coagulation activity when 
heparin is inhaled directly into the airways.  
Currently, there are no clinically available therapies that prevent COPD disease progression.  
Inhaled heparin may therefore represent an effective add-on therapy in COPD and asthma 
patient groups, especially when taking into consideration the relative deficiency in 
endogenous heparin reported in asthma patients [20].  Overall, we believe that the multiple 
pharmacological effects of inhaled unfractionated heparin are likely to have greater 
therapeutic benefit in patients with asthma and COPD than compounds acting against a 
single target.  
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Figure 1. Potential mechanisms of action of inhaled unfractionated heparin in the treatment of asthma and COPD  
Anti-inflammatory; 
• Inhibition of chemokines eg IL-8  
• Inhibition of neutrophil elastase and 
cathepsin G.  
• Inhibition of complement activation 
• Neutralisation of eosinophil basic 
proteins eg ECP 
 Mucoregulatory; 
• Inhibits neutrophil elastase/IL-13/oxidant-
induced mucus hypersecretion 
• Inhibits ECP-induced C-fibre stimulation of 
mucus hypersecretion 
• Inhibits MUC5AC mRNA expression in airway 
epithelial cells 
Mucolytic;  
• Dissociates DNA/protein 
aggregates in sputum 
• Activates DNases to degrade 
extracellular DNA in sputum 
• Reduces electrostatic 
interaction between mucins 
Anti-oxidant; 
• Inhibition of free radical 
release from activated 
neutrophils 
• Increased expression 
and activity of EC-SOD 
Anti-nitrosant; 
• Inhibits iNOS 
expression 
Decreased airway obstruction 
Increased airflow 
Improved delivery of other 
inhaled drugs 
Decreased ECP/elastase/oxidant/iNOS- 
induced pulmonary tissue damage 
Decreased bronchial hyperreactivity 
Increased rate of wound repair 
Reparative; 
• Growth factor binding and 
activation (FGF-2, TGFβ) 
• Release and activation of 
growth factors from tissue 
binding sites 
Inhaled Unfractionated 
Heparin 
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Author (year) Study design Drug and dose Patients Clinical condition Therapeutic outcome 
Boyle et al.  
(1964).
 
Am J 
Cardiol;14:25-8. 
 
Double blind placebo 
(saline) controlled. 
UFH - IV. 
20,000 IU 
followed by 
10,000 IU for 3 
more doses 
every 12 h. 
N=19 in test arm 
N=20 in control 
arm 
Equal numbers in 
groups A and B 
A: Status asthmaticus 
or B: chronic  
bronchopulmonary 
disease with 
bronchospasm and 
tenacious secretions 
Release of bronchospasm and 
elimination of obstructing mucus in 
11 patients. 
Youngchaiyud et 
al. (1969) 
Am Rev Resp 
Dis;99:449-452 
 
 
Open label. Placebo 
(saline and heparin 
vehicle) controlled  
Inhaled, 
nebulised UFH 
20,000 IU in 1 
ml 0.5% 
phenol -saline 
control. 
N=20 in test arm 
N=17 in saline arm 
N=18 in 0.5% 
phenol vehicle 
control arm 
COPD patients. 
FEV1/FVC = 36-49% 
Both heparin and the vehicle control 
induced expectoration. An 
expectorant action was not 
attributable to heparin. Heparin 
increased airway conductance, not 
seen in either control group. 
Brown et al 
(2006) 
Pulm Pharmacol 
Ther;19:419-24. 
 
Randomised parallel 
group. No control, 
treatment added to 
inhaled fixed dose 
salmeterol/fluticasone 
LMWH 
enoxaparin,     
20 mg – SC, 
once a day for 
12 weeks 
N=20 in control 
arm 
N=16 in treatment 
(completed) 
Stable COPD 
FEV1; Control mean 
46.8% predicted,    
Test mean 47.8% 
predicted 
Significant improvement in lung 
function by 4 weeks with enoxaparin, 
but in control, significant 
improvement only seen at 12 weeks. 
Shi X & Li H  
(2013) 
Exp Ther 
Med;5:1367-1370 
 
Randomised, open 
label 
4100 IU 
LMWH-Ca 
(SC), bd, for 
10 days 
N=32 control, 
N=38 treated plus 
standard therapy 
Acute exacerbation of 
COPD, on admission 
Improved pulmonary 
function>control. Improved 
hypercoagulative state in treated 
group, not in control. 
Qian et al  
(2014) 
COPD;11:171-6. 
 
Randomised, open 
label. 
LMWH 
nadroparin 
(SC) plus 
standard 
therapy for  
7 days 
N=33 control 
(standard therapy) 
N=33 test arm 
(standard therapy 
plus LMWH 
COPD acute 
exacerbation, in 
mechanically ventilated 
patients 
Plasma CRP, IL-6, and fibrinogen 
were significantly decreased in the 
LMWH group. LMWH significantly 
reduced the mean duration of 
mechanical ventilation, the length of 
ICU and hospital stay (14.3 days vs. 
11.3 days; p <0.01). 
Shute et al 
(2018).               
Pulm Pharmacol 
Ther.  48: 88-96 
Randomised, three 
parallel groups, 
double blind. 
Inhaled UFH, 
75,000 or 
150,000 IU bd 
for 21 days. 
Aerosolised 
water control. 
N= 9, placebo 
(water) 
N= 6, 75,000 IU 
N=9, 150,000 IU 
(completed) 
COPD, post-
exacerbation 
FEV1%; 
Placebo; 50.45±3.12, 
75,000;48.57±2.25, 
150,000;41.53±2.51 
No systemic anti-coagulation. 
Significant improvement in FEV1 at 7 
days with 150,000 IU. At 21 days 
significant effect on gas trapping at 
high dose. Improvement in exercise 
capacity and dyspnea with both 
doses. 
Table 1; Studies of UFH and LMWH in patients with COPD.                     
UFH; unfractionated heparin, LMWH; low molecular weight heparin, IV; intravenous, SC; subcutaneous. 
